Time filter

Source Type

Corrales-Rodriguez L.,Medical Oncologist | Soulieres D.,Center Hospitalier Of Luniversite Of Montreal | Weng X.,Center Hospitalier Of Luniversite Of Montreal | Tehfe M.,Center Hospitalier Of Luniversite Of Montreal | And 2 more authors.
Thrombosis Research | Year: 2014

Introduction The association of venous thromboembolic events (VTE) and lung cancer is highly prevalent. Additionally, the occurrence of a VTE with cancer has been associated with a worse prognosis and a poor quality of life. Underlying cancer biological features such as tumour mutations may contribute to VTE risk and cancer prognosis. Since preclinical data suggest a link between thrombosis and KRAS mutations in tumours, we aimed to validate this association in a patient registry cohort. Methods: A retrospective case control study was performed using the CHUM NSCLC registry. Cases had VTE occurring 6 months previous to or after a diagnosis of NSCLC. Diagnosis of VTE (venous thrombosis, pulmonary embolism, and migratory superficial thrombophlebitis) was confirmed by a review of the imaging reports. Controls were patients with NSCLC without thrombosis matched for age and stage (I-IIIA/IIIB-IV). Exclusion criteria included insufficient tissue for KRAS/EGFR mutation analysis or insufficient clinical information. Results Between Jan 2000 and Dec 2009 a total of 57 cases with VTE and 102 controls without VTE were included. The OR for thrombosis in KRAS and EGFR mutated NSCLC patients are respectively 2.67 (1.12-6.42; p = 0.014) and 0.99 (0.27-3.48; p = 0.99). Conclusions KRAS mutation is associated with an increased risk of VTE in this NSCLC cohort. These findings are consistent with preclinical studies. Prospective data on VTE rates from clinical trials with molecularly defined NSCLC are needed to confirm these findings. © 2013 Elsevier Ltd. All rights reserved.

Malik A.,AFMC | Veniyoor A.,Medical Oncologist | Fanthome B.,Consultant Onco Surgery | Dutta V.,AFMC
Journal of Cancer Research and Therapeutics | Year: 2012

Follicular dendritic cell sarcoma (FDCS) is a spindle cell neoplasm of histiocytic-dendritic cells origin. It is known to occur in lymph nodes and rarely has been reported in extranodal tissues like head and neck, mediastinum and gastrointestinal tract. We herein report the first FDCS arising from anal canal in a 56-year-old man. The tumor was composed of bland short spindle cells in focal whorl formation with interspersed few lymphocytes. The tumor cells were classically positive for CD21, CD23, CD35 and vimentin. Despite its misleading morphology, immunohistochemistry helped us to reach a conclusive diagnosis for relevant therapy.

Papaloucas C.D.,Democritus University of Thrace | Papaloucas M.D.,University of Peloponnese | Kouloulias V.,National and Kapodistrian University of Athens | Neanidis K.,Medical Oncologist | And 5 more authors.
Medical Hypotheses | Year: 2014

The possible elevation of phosphorous (P) in cancer patients blood serum has been reported in the past. This however seems to have passed unnoticed. One hundred individuals, divided into two groups of fifty each, i.e. cancer patients (group A) and healthy individuals (group B), were included in this retrospective study. The incidence of cancer by site in group A was 24% head and neck, 50% non-small cell lung cancer (SCLC) and 26% cervical cancer. In all cancer patients in group A the serum P was over the normal values, in contrast with the normal values of P measured in group B. The mean value of serum P in group A and B were 7.80 (±2.24) and 3.38 (±0.58), respectively (P<. 0.001, Mann Whitney test). Increased amount of phosphorus in the blood, when other causes justifying the increase were excluded, should be considered as indicative for the existence of unidentified cancerous lesions. © 2013 Elsevier Ltd.

Molina-Garrido M.J.,Virgen de la Luz General Hospital | Guillen-Ponce C.,Medical Oncologist
European Oncology and Haematology | Year: 2012

The field of oncogeriatrics considers the comprehensive geriatric assessment (CGA) as the main tool for distinguishing between patients who are frail and those who are not frail. The aim of our study was to determine the role of the CGA in predicting the risk of frailty in elderly patients. This prospective study was conducted at the Cancer in the Elderly Unit of the Medical Oncology Department at the Virgen de la Luz General Hospital in Cuenca, Spain. Demographic data and information about the CGA were collected. Using a bivariate logistic regression analysis, these factors were analysed and the factors that are associated with the risk of frailty were determined, as measured by the Barber questionnaire (BQ). We included 262 patients in the study with a mean age of 79 years (range 70-93 years). Seventy-four percent of the patients (n=194) had a risk of frailty as measured by the BQ. In the bivariate analysis, only age (odds ratio [OR] 1.064, 95 % confidence interval [CI] 1.000-1.133, p=0.051), being divorced, widowed or single (OR 0.450, 95 % CI 0.216-0.937, p=0.033) and being dependent in instrumental activities of daily living (IADL) (OR 3.003, 95 % CI 1.181-7.638, p=0.021) were associated with a higher risk of frailty. The risk of being frail in an elderly patient with cancer is higher in patients dependent in IADL and in patients who are not married. Age is another risk factor for frailty. © Touch Briefings 2012.

Karadimou A.,Medical Oncologist | Makatsoris T.,University of Patras
Forum of Clinical Oncology | Year: 2013

Neuroendocrine tumors (NETs) comprise a group of relatively rare neoplasms with very complex and heterogeneous clinical behavior. The incidence of these tumors according to recent epidemiological studies has been remarkably increased worldwide. This is not only due to increasing detection using new improved imaging techniques but it also seems to reflect the increase of knowledge and awareness in dealing with this real diagnostic challenge. Given their diverse biological behavior and therapeutic approaches, a proper classification of NETs is warranted. Recently, two new molecularly targeted agents, sunitinib that targets the vascular endothelial growth factor (VEGF) pathway, and everolimus that targets the mammalian target of rapamycin (mTOR) pathway, have been approved for the treatment of pancreatic neuroendocrine tumors. Here, we will review the major advances in diagnosis, classification and treatment of NETs.

Discover hidden collaborations